ClinicalTrials.gg
No longer availableNCT03672968Updated Mar 2, 2026

EAP_GS010_single Patient

An expanded access record providing GS010 in Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber), sponsored by GenSight Biologics. No longer available. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by GenSight Biologics · Expanded access

Study type
Expanded access
Access type
Individual patients
Sex
All
01

Study summary

Expanded Access Use for a single patient of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected with G11778A ND4 Leber Hereditary Optic Neuropathy

02

Conditions studied

  • Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)

Keywords

  • Heredity Optic Atrophy
  • Leber Hereditary Optic Atrophy
  • Leber Hereditary Optic Neuropathy
  • LHON
  • Eye Diseases
  • Hereditary Eye Diseases
  • Inherited retinal dystrophies or degeneration
  • Inborn Genetic Disease
  • Gene Therapy
  • Intravitreal Injections
  • Mitochondrial Disease
  • AAV2 Vectors
  • Neurodegenerative Disease
  • Atrophy
03

In context

Optic Atrophy, Hereditary, Leber

44 studies on the registry are indexed under Optic Atrophy, Hereditary, Leber; 9 are open to participants now.

Browse Optic Atrophy, Hereditary, Leber studies →

Lead sponsor

GenSight Biologics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The EAP applies to patients not eligible to ongoing GS010 clinical trials.

Inclusion criteria

Inclusion Criteria:

  • Presence of documented G11778A ND4 LHON-causing mutation
  • Signature of and assent from the parent/guardian and the patient.

Exclusion criteria

Exclusion Criteria:

to GS010 product or IVT procedures are to be checked prior to consent signature and treatment injection:

  • Any known allergy or to GS010 or its constituents.
  • Contraindication to intravitreal injection in any eye.
  • Intravitreal drug delivery to any eye within 30 days prior to the injection
  • Previous vitrectomy in either eye.
  • Narrow angle in any eye contra-indicating pupillary dilation.
  • Presence of disorders or diseases of the eye or adnexa, excluding LHON, which may interfere with visual or ocular assessments, including SD-OCT, during the study period.
  • Presence of known/documented mutations, other than the G11778A ND4 LHON-causing mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system.
  • Presence of systemic or ocular/vision diseases, disorders or pathologies, other than LHON, known to cause or be associated with vision loss, or whose associated treatment(s) or therapy(ies) is/are known to cause or be associated with vision loss.
  • Presence of optic neuropathy from any cause except LHON.
  • Presence of illness or disease that, in the opinion of the Investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system, including Multiple Sclerosis (diagnosis of Multiple Sclerosis must be based on the 2010 Revisions to the McDonald Criteria [Polman 2011]).
  • History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation.
  • Previous treatment with ocular gene therapy in either eye.
  • Subjects who have undergone ocular surgery of clinical relevance (per Investigator assessment) within 90 days prior to injection.
  • Subjects who are unable to tolerate (e.g. the immune modulating regimen) or unable or unwilling to comply with all the protocol requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • GeneticGS010
06

Where to request access

No study locations are listed for this record.

07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03672968
Lead sponsor
GenSight Biologics
Responsible party
Sponsor
First posted
Sep 17, 2018
Last update
Mar 2, 2026
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion